149 compounds. Every one graded.

Once-weekly amylin analogue for weight loss

Cagrilintide is a long-acting acylated amylin analogue developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It mimics the pancreatic hormone amylin to reduce appetite, slow gastric emptying, and promote satiety. In clinical trials, it has been studied both as a monotherapy and in combination with semaglutide (as CagriSema), demonstrating meaningful and sustained body weight reduction.

Dual amylin-GLP-1 therapy for superior weight loss

Cagrisema is a fixed-ratio combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), each at 2.5 mg per dose. This dual-hormone therapy is designed to provide additive and potentially synergistic effects on appetite suppression, glycemic control, and body weight reduction beyond what either agent achieves alone. It is currently under clinical investigation by Novo Nordisk for the treatment of obesity and type 2 diabetes.

Oxygen-boosting hormone for endurance and anemia

Erythropoietin (EPO) is a glycoprotein hormone naturally produced primarily by the kidneys that regulates red blood cell production. Recombinant human EPO (rHuEPO) mimics this endogenous hormone to stimulate erythropoiesis in the bone marrow, increasing oxygen-carrying capacity. It is clinically approved for anemia associated with chronic kidney disease, chemotherapy, and certain other conditions, but is also widely misused as a performance-enhancing agent in endurance sports.

Dual GLP-1/glucagon agonist for metabolic health

Mazdutide is a dual GLP-1/glucagon receptor co-agonist peptide developed by Innovent Biologics, originally derived from oxyntomodulin. It simultaneously activates both GLP-1 and glucagon receptors to produce robust reductions in body weight, blood glucose, and hepatic fat. Clinical trials in China have demonstrated significant efficacy for obesity and type 2 diabetes management.

Tissue-protective peptide for nerve repair and inflammation

ARA290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface peptide of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis. It is designed to harness the tissue-protective and anti-inflammatory properties of EPO while avoiding its hematopoietic side effects. Clinically, it has been investigated for neuropathic pain, small fiber neuropathy, and inflammatory conditions such as sarcoidosis.

Cardiac peptide bioregulator for heart longevity

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, designed to support cardiac tissue health and function. It acts as a cytoprotective bioregulator targeting cardiomyocytes, promoting cellular repair and reducing age-related deterioration in heart muscle tissue. Research, primarily from Russian preclinical and limited clinical studies, suggests it may help maintain cardiac contractility, reduce fibrosis, and support overall cardiovascular resilience.

Potent GH secretagogue with cardiac benefits

Hexarelin Acetate is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) that stimulates pituitary release of growth hormone (GH) by mimicking the action of ghrelin. It binds to the GHS-R1a receptor with high affinity and also exhibits direct cardioprotective effects independent of GH release. Developed originally as a potential treatment for GH deficiency, it is one of the most potent GH-releasing peptides studied in clinical research.

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

Biased RXFP1 agonist for cardiac fibrosis

B7-33 is a single-chain peptide analog of human relaxin-2, engineered to selectively activate the RXFP1 receptor without triggering the cAMP signaling pathway. It demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective effects in preclinical models. Research primarily focuses on its potential in heart failure, pulmonary arterial hypertension, and organ fibrosis.

Targeted fat-depot elimination via vascular apoptosis

Adipotide is a pro-apoptotic peptidomimetic designed to selectively destroy the blood supply feeding white adipose tissue (WAT), causing fat cell death through targeted vascular disruption. It was developed at MD Anderson Cancer Center primarily as an anti-obesity compound and has shown dramatic fat loss in non-human primate studies. Human clinical data remains extremely limited, and it is considered a research compound only.

Antidiuretic hormone peptide

Antidiuretic hormone for water retention & blood pressure.

Electrolyte balance and cardiovascular metabolic support

KLOW is a research compound or proprietary peptide blend purported to support electrolyte balance, cardiovascular function, and cellular metabolic homeostasis. It is marketed within the peptide research space, though its precise composition and mechanism are not well-established in peer-reviewed literature. Evidence for its specific effects remains largely anecdotal and preclinical.